Clinical trials for ALK-negative anaplastic large cell lymphoma
14 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 3NCT07300514Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University · PI: Rong Tao, MD &PhD
- RECRUITINGPhase 2NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaJonathan Brammer · PI: Jonathan Brammer, MD
- RECRUITINGPhase 1NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine · PI: Premal Lulla, MD
- RECRUITINGPhase 1NCT07001384A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)Memorial Sloan Kettering Cancer Center · PI: Robert Stuver, MD
- ACTIVE NOT RECRUITINGPhase 2NCT07013565Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLNew York Medical College · PI: Mitchell S Cairo, MD
- RECRUITINGPhase 2NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaYale University · PI: Tarsheen Sethi, MD
- RECRUITINGPhase 1NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaMayo Clinic · PI: Kah Whye Peng, PhD
- RECRUITINGPHASE1, PHASE2NCT04925609Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsPrincess Maxima Center for Pediatric Oncology · PI: Michel Zwaan, Prof
- ACTIVE NOT RECRUITINGPhase 4NCT05160922Crizotinib Continuation Clinical StudyPfizer · PI: Pfizer CT.gov Call Center
- RECRUITINGPhase 3NCT05075460Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell LymphomaPeking Union Medical College Hospital · PI: Daobin Zhou
- ACTIVE NOT RECRUITINGPhase 2NCT04331119Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell LymphomasWashington University School of Medicine · PI: Amanda Cashen, M.D.
- RECRUITINGPHASE1, PHASE2NCT04094610A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsTurning Point Therapeutics, Inc. · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGPhase 2NCT03703050Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)Gustave Roussy, Cancer Campus, Grand Paris · PI: Véronique Minard, Pr
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02223208Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell LymphomasFondazione Italiana Linfomi - ETS · PI: Paolo Corradini, Prof